L
Li Lin
Researcher at Huazhong University of Science and Technology
Publications - 20
Citations - 1887
Li Lin is an academic researcher from Huazhong University of Science and Technology. The author has contributed to research in topics: STAT3 & Cancer. The author has an hindex of 18, co-authored 20 publications receiving 1709 citations. Previous affiliations of Li Lin include The Research Institute at Nationwide Children's Hospital & Ohio State University.
Papers
More filters
Journal ArticleDOI
STAT3 Is Necessary for Proliferation and Survival in Colon Cancer–Initiating Cells
TL;DR: It is established that STAT3 is constitutively activated in colon cancer-initiating cells and that these cells are sensitive to STAT3 inhibition, a powerful rationale to develop STAT3 inhibitory strategies for treating advanced colorectal cancers.
Journal ArticleDOI
Novel STAT3 Phosphorylation Inhibitors Exhibit Potent Growth-Suppressive Activity in Pancreatic and Breast Cancer Cells
Li Lin,Brian Hutzen,Mingxin Zuo,Sarah Ball,Stephanie Deangelis,Elizabeth Foust,Bulbul Pandit,Michael A. Ihnat,Satyendra S. Shenoy,Samuel K. Kulp,Pui-Kai Li,Chenglong Li,James R. Fuchs,Jiayuh Lin +13 more
TL;DR: FLLL31 and FLLL32 are effective inhibitors of STAT3 phosphorylation, DNA-binding activity, and transactivation in vitro, leading to the impediment of multiple oncogenic processes and the induction of apoptosis in pancreatic and breast cancer cell lines.
Journal ArticleDOI
A novel small molecule, LLL12, inhibits STAT3 phosphorylation and activities and exhibits potent growth-suppressive activity in human cancer cells.
Li Lin,Brian Hutzen,Pui-Kai Li,Sarah Ball,Mingxin Zuo,Stephanie Deangelis,Elizabeth Foust,Matthew Sobo,Lauren Friedman,Deepak Bhasin,Ling Cen,Ling Cen,Chenglong Li,Jiayuh Lin +13 more
TL;DR: Results indicate that LLL12 may be a potential therapeutic agent for human cancer cells expressing constitutive STAT3 signaling and demonstrates a potent inhibitory activity on breast and glioblastoma tumor growth in a mouse xenograft model.
Journal ArticleDOI
Targeting colon cancer stem cells using a new curcumin analogue, GO-Y030
Li Lin,Yan Liu,Li H,Pui-Kai Li,James R. Fuchs,Hiroyuki Shibata,Yoshiharu Iwabuchi,Jiayuh Lin +7 more
TL;DR: The results indicate that STAT3 is a novel therapeutic target in colon cancer stem cells, and inhibition of activated STAT3 in cancerstem cells by GO-Y030 may offer an effective treatment for colorectal cancer.
Journal ArticleDOI
A novel small molecule inhibits STAT3 phosphorylation and DNA binding activity and exhibits potent growth suppressive activity in human cancer cells
Li Lin,Li Lin,Stephanie Deangelis,Elizabeth Foust,James R. Fuchs,Chenglong Li,Pui-Kai Li,Eric B. Schwartz,Gregory B. Lesinski,Don M. Benson,Jiagao Lü,Dale G. Hoyt,Jiayuh Lin +12 more
TL;DR: Findings indicate that FLLL32 exhibits potent inhibitory activity to STAT3 and has potential for targeting multiple myeloma, glioblastoma, liver cancer, and colorectal cancer cells expressing constitutive STAT3 signaling.